Replicel Life Sciences Inc
XTSX:RP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Replicel Life Sciences Inc
XTSX:RP
|
CA |
|
Frontier Resources Ltd
ASX:FNT
|
AU |
|
Nippon Life India Asset Management Ltd
NSE:NAM-INDIA
|
IN |
|
Brunswick Corp
NYSE:BC
|
US |
|
L
|
Lucero Energy Corp
XTSX:LOU
|
CA |
|
L
|
Laybuy Holdings Ltd
ASX:LBY
|
NZ |
|
Mill City Ventures III Ltd
NASDAQ:MCVT
|
US |
|
A
|
AmeriGuard Security Services Inc
OTC:AGSS
|
US |
|
South32 Ltd
ASX:S32
|
AU |
|
M
|
MedNation AG
SWB:EIF
|
DE |
|
Samudera Shipping Line Ltd
SGX:S56
|
SG |
|
Veeco Instruments Inc
NASDAQ:VECO
|
US |
|
Xin Point Holdings Ltd
HKEX:1571
|
CN |
|
G
|
Goldhills Holding Ltd
XTSX:GHL
|
CA |
|
Atlantica Sustainable Infrastructure PLC
NASDAQ:AY
|
UK |
|
Experian PLC
LSE:EXPN
|
IE |
|
I
|
Israel Petrochemical Enterprises Ltd
TASE:PTCH
|
IL |
|
Blue Sphere Corp
OTC:BLSP
|
US |
|
Technical Communications Corp
OTC:TCCO
|
US |
|
51 Credit Card Inc
HKEX:2051
|
CN |
|
T
|
Topsports International Holdings Ltd
HKEX:6110
|
CN |
|
L
|
Lineage Cell Therapeutics Inc
TASE:LCTX
|
US |
|
Sendas Distribuidora SA
BOVESPA:ASAI3
|
BR |
|
Maharashtra Seamless Ltd
NSE:MAHSEAMLES
|
IN |
Replicel Life Sciences Inc
RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in the development of autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopeci, and skin aging. The company is headquartered in Vancouver, British Columbia and currently employs 1 full-time employees. The company went IPO on 2012-09-29. The company is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.
RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in the development of autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopeci, and skin aging. The company is headquartered in Vancouver, British Columbia and currently employs 1 full-time employees. The company went IPO on 2012-09-29. The company is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.
